Clinical Trials

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT02193282 2026-03-18

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

390 enrolled

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02194738 2026-03-18

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

8,300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03233711 2026-03-18

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

344 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT03244384 2026-03-18

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT03811015 2026-03-18

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT06498635 2026-03-18

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03055013 2026-03-17

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT07388524 2026-03-17

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

336 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05812807 2026-03-04

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05976763 2026-03-04

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

421 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

1,150 enrolled 6 charts

Dermatologic

Melanoma

NCT06647953 2026-02-24

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Phase 4 Not yet recruiting

110 enrolled

Pleuropulmonary blastoma

NCT07281547 2026-02-18

Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

25 enrolled

Gynecologic

Endometrial Neoplasms

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Recruiting

120 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05333874 2026-02-09

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Phase EARLY_PHASE1 Active not recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06733350 2026-02-09

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Suspended

600 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

396 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07370675 2026-01-27

Active Surveillance for Bethesda IV Thyroid Nodules

Phase NA Recruiting

165 enrolled

Head & Neck

Thyroid Neoplasms, Thyroid Nodule

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

1 enrolled

Phase EARLY_PHASE1 Recruiting

Colonic Neoplasms

NCT07025226 2026-01-26

Senolytics

10 enrolled

CNS

Glioma

NCT02914873 2026-01-20

PCASTT

Phase NA Active not recruiting

2,008 enrolled

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07240220 2026-01-15

Merck-4

2,500 enrolled

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

NCT03180268 2026-01-14

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

163 enrolled

CNS

Meningioma

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

532 enrolled

Prostatic Neoplasms

NCT03803553 2025-12-23

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

400 enrolled

Colonic Neoplasms

NCT02176967 2025-12-22

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

621 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03533582 2025-12-22

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

537 enrolled

Fibrolamellar hepatocellular carcinoma, Hepatoblastoma

NCT02201992 2025-12-19

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

166 enrolled